Fund HIV Vaccine Research & Development
Summary
NIH is offering Research Project Grants (R01) to support hypothesis-driven basic research focused on discovering an effective prophylactic HIV vaccine. Eligible entities can receive funding to explore new concepts and approaches in HIV/AIDS, virology, and immunology to advance vaccine design.
Eligibility
Full Description
-Purpose. The aim of this Funding Opportunity Announcement (FOA) issued by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), is to stimulate the discovery of an effective prophylactic HIV vaccine by soliciting Research Project Grant (R01) applications for hypothesis-driven basic research in HIV/AIDS, and general virology and immunology that is focused on directly achieving that aim. The emphasis is on discovery research, including the identification of new concepts and approaches that will inform the design of an optimal prophylactic HIV vaccine design, and the implementation of concepts and/or approaches employed successfully in the development of vaccines for other infections. -Mechanism of Support.
This FOA will utilize the NIH Research Project Grant (R01) award mechanism.-Funds Available and Anticipated Number of Awards. NIAID intends to commit approximately $10M in total costs in FY 2009 to fund 20-30 applications submitted in response to this FOA. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.